SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide
- PMID: 37385274
- DOI: 10.1016/S0140-6736(23)01292-8
SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide
Conflict of interest statement
CSF reports payment from Novo Nordisk for one educational event about hormonal therapy in menopause (May, 2023). SM reports travel support to attend EASD 2023 from Boehringer Ingelheim and advisory boards fees from Bayer AC for discussion of the place of finerenone in the treatment of type 2 diabetes, and lecture fees from Novo Nordisk for a talk on GLP-1 receptor agonists in type 2 diabetes at the Hong Kong Society of Endocrinology, Metabolism, and Reproduction and Hong Kong Public Hospital Cardiologists Association in June, 2023.
Comment on
-
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. Lancet. 2023. PMID: 37385275 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical